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Abstract
This phase II trial was intended to investigate 2 doses of bavituximab (a phosphatidylserine-targeting antibody)
or placebo combined with docetaxel in previously treated, advanced nonsquamous nonesmall-cell lung
cancer. Because of a labeling discrepancy, the placebo and bavituximab 1 mg/kg arms were combined and
compared with the bavituximab 3 mg/kg arm. This exploratory analysis showed similar toxicity between arms,
and albeit without meeting the preset statistical end points because of the pooled control arm data, had trends
favoring bavituximab 3 mg/kg.
Background: Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed im-
mune response. In this phase II trial the efﬁcacy and safety of bavituximab combined with docetaxel for previously
treated, advanced nonsquamous nonesmall-cell lung cancer were evaluated. Patients and Methods: Patients were
randomized 1:1:1 to receive docetaxel 75 mg/m2 every 21 days for up to 6 cycles combined with weekly, blinded
infusions of placebo, bavituximab 1 mg/kg, or bavituximab 3 mg/kg until disease progression or unacceptable toxicity.
The primary end point was overall response rate (ORR), with a predeﬁned end point of 26% in the bavituximab arms.
After study unblinding, vial-coding discrepancies were discovered in the placebo and bavituximab 1 mg/kg groups. In
exploratory analyses, data from these groups were pooled to form the control group and compared with the 3 mg/kg
group. Results: Efﬁcacy end points in the bavituximab 3 mg/kg group (n ¼ 41) and in the placebo/bavituximab 1 mg/
kg group (n ¼ 80), respectively, were as follows: ORR, 17.1% (95% conﬁdence interval [CI], 5.6%-28.6%) and ORR,
11.3% (95% CI, 4.3%-18.2%); median progression-free survival 4.5 and 3.3 months (hazard ratio [HR], 0.74 [95% CI,
0.45-1.21]; P ¼ .24); median overall survival 11.7 and 7.3 months (HR, 0.66 [95% CI, 0.40-1.10]; P ¼ .11). Toxicities
were manageable and similar between arms. Conclusion: The combination of bavituximab and docetaxel is well
tolerated. Although no ﬁrm efﬁcacy conclusions can be drawn and the trial did not meet the predeﬁned primary end
point, exploratory analyses suggest trends favoring the combination of bavituximab 3 mg/kg with docetaxel. This
regimen is being evaluated in the ongoing, global, phase III SUNRISE trial.
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Recently, immunotherapy has emerged as a promising treatment
strategy for advanced nonesmall-cell lung cancer (NSCLC).ClinicalTrials.gov identiﬁer: NCT01138163.
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Docetaxel and Bavituximab in Nonsquamous NSCLC(FDA) approved the anti-PD1 agent nivolumab for the treatment of
previously treated, advanced NSCLC after pivotal phase III trials
reported superior efﬁcacy compared with docetaxel chemotherapy in
squamous and nonsquamous populations.1,2 The FDA also
approved the anti-PD1 antibody pembrolizumab for PDL1-positive
advanced NSCLC.3
In addition to and distinct from the widely studied immune
checkpoints PD1, PDL1, and cytotoxic T-lymphocyte antigen 4
(CTLA4), the anionic phospholipid phosphatidylserine (PS) has
been recognized for decades for exerting immunosuppressive phys-
iologic effects.4-6 Speciﬁcally, exposed PS on apoptotic cells sup-
presses immune and inﬂammatory responses by binding to
macrophage PS receptors, thereby signaling macrophage production
of anti-inﬂammatory cytokines such as TGFb and interleukin (IL)-
10 and preventing dendritic cell maturation and antigen presenta-
tion.7 In preclinical models, PS-targeting antibodies counter both of
these effects, resulting in production of proinﬂammatory cytokines
such as tumor necrosis factor-a and IL-1b, as well as induction of
cytotoxic T-lymphocyte immunity.8 PS targeting also results in
antivascular effects. Speciﬁcally, upon binding of anti-PS antibodies
to tumor vessels, bavituximab activates host effector (immune)
functions, such as antibody-dependent cellular cytotoxicity
(ADCC), resulting in rapid vessel destruction and subsequent tu-
mor necrosis.9
Because of differential exposure in malignant tissues, PS is a
relatively tumor-speciﬁc therapeutic target. In most tissues, PS is
restricted to the internal surface of the cell membrane.10 In contrast,
within solid tumors, hypoxia and other physiologic stresses disrupt
this asymmetry. These processes result in exposure of PS on the
outer membrane leaﬂet, where it is available for binding by PS-
targeting therapies.11,12 There might be differences in expression
of PS in different tumor types. A study of PS exposure in cell lines
derived from a variety of malignant melanomas, prostate cancer,
renal cancer, glioblastoma, and rhabdomyosarcoma reported PS
exposure in the rhabdomyosarcoma cell line to be signiﬁcantly
higher than the amount in the malignant melanoma cell line,
whereas levels in the glioblastoma cell line were lower.13
Bavituximab is an unconjugated, chimeric immunoglobulin G1
monoclonal antibody (mAb) that localizes to anionic phospholipids
expressed on tumor endothelium, principally PS. In preclinical
models of multiple tumor types, bavituximab inhibits tumor
growth, prolongs survival, and enhances the effects of chemotherapy
and radiation.12,14,15 Preclinical models have also shown tumor-
speciﬁc targeting by bavituximab.11,16,17 Additionally, the admin-
istration of cytotoxic therapies, including chemotherapy and
ionizing radiation, further induces PS exposure, thereby enhancing
bavituximab binding and resulting in complementary effects when
combined with bavituximab.14,15
In a phase I trial of bavituximab in relapsed and refractory ma-
lignancies, no maximum tolerated dose was reached.18 The 1 mg/kg
and 3 mg/kg weekly doses were well tolerated and, on the basis of
preclinical pharmacokinetic (PK) modeling, were considered the
likely preferred biologic doses. Considerations included antitumor
efﬁcacy, possible depletion of cofactor protein b2-glycoprotein 1,
tolerability, and ADCC. In single-arm combination studies with
cytotoxic chemotherapy, the additional use of bavituximab generally
did not increase the risk of adverse events (AEs).19,20 AlthoughClinical Lung Cancer May 2016limited by lack of comparator arms, results of these trials also sug-
gest that the additional use of bavituximab might enhance the ef-
ﬁcacy of chemotherapy. In the ﬁrst-line setting for advanced
NSCLC, the use of the combination carboplatin-paclitaxel with
bavituximab resulted in a response rate of 41%.19 In patients with
HER2-negative breast cancer, the use of paclitaxel with bavituximab
resulted in a response rate of 80%, and bavituximab administration
increased numbers of circulating PS-positive apoptotic tumor
cells.20 On the basis of these data, we hypothesized that the com-
bination of bavituximab with docetaxel chemotherapy would be
well tolerated and would improve clinical outcomes in previously
treated, advanced nonsquamous NSCLC.
Patients and Methods
This was designed to be a prospective, randomized, double-blind,
placebo-controlled, multicenter, 3-arm, phase II study (see
Supplemental Figure 1 in the online version). Patients were intended
to be randomized (1:1:1) to docetaxel with placebo, docetaxel with
bavituximab 1 mg/kg, or docetaxel with bavituximab 3 mg/kg.
However, because of labeling discrepancies of the blinded investiga-
tional product, some patients in the placebo group received some
doses of bavituximab 1mg/kg, and some patients in the bavituximab 1
mg/kg group received some doses of placebo (see Results). Patients in
the bavituximab 3mg/kg groupwere not affected by these events. The
primary end point of this trial was overall response rate (ORR;
complete responseþ partial response), assessed using an independent,
blinded, central radiology review. Secondary end points included
progression-free survival (PFS), duration of response, overall survival
(OS), safety, and PK parameters to assess drugedrug interaction. PFS
was a secondary end point, and because there were more events (less
censoring) on the basis of investigator assessment, which accounted
for the clinical progression compared with the PFS estimate on the
basis of central review of solely radiographic data, we chose to report
PFS according to investigator assessment.
This study (NCT01138163) was conducted according to the
Declaration of Helsinki and with approval from the institutional
review boards of all participating study sites. All participants pro-
vided written informed consent before any study-related procedures.
Patient Population
Eligible candidates for this study had histologically or cytologi-
cally conﬁrmed advanced stage, nonsquamous NSCLC with disease
progression after treatment with platinum-based doublet chemo-
therapy. Squamous histology was excluded because of the devel-
opment of Grade 5 hemoptysis in a patient with advanced
squamous NSCLC in the setting of progressive tumor cavitation
and therapeutic response in an earlier trial of carboplatin/paclitaxel
with bavituximab.21 Previous docetaxel treatment was not
permitted. Previous bevacizumab or tyrosine kinase inhibitor ther-
apy was allowed. Additional eligibility criteria included the presence
of measurable disease (according to Response Evaluation Criteria in
Solid Tumors 1.1),21 Eastern Cooperative Oncology Group
(ECOG) performance status 0 to 2, life expectancy of at least 3
months, adequate bone marrow, adequate renal function, adequate
hepatic function, and coagulation parameters. Patients were
excluded if they had New York Heart Association class III or IV
cardiac disease, a known history of bleeding diathesis or
David E. Gerber et alcoagulopathy, cavitary tumors, or tumors abutting large blood
vessels, clinically signiﬁcant bleeding within 12 months (unless the
cause was identiﬁed and adequately treated), symptomatic cardiac or
cerebrovascular disease within 6 months, ongoing use of anticoag-
ulants, Grade  2 peripheral neuropathy, or clinically active brain
metastases. Per the study protocol, brain magnetic resonance im-
aging was not required for eligibility and was not performed
routinely, but could be performed at the discretion of the treating
physician if brain involvement was suspected. Testing for epidermal
growth factor receptor (EGFR) mutations or anaplastic lymphoma
kinase (ALK) rearrangements were not required for eligibility, nor
were EGFR or ALK status captured for trial participants.
Study Treatment
Patients received docetaxel 75 mg/m2 intravenously (i.v.) on
day 1 of a 21-day cycle with blinded study treatment (either
placebo weekly, bavituximab 1 mg/kg weekly, or bavituximab 3
mg/kg weekly) for up to 6 cycles. Before administration of blinded
study treatment, which was given at least 30 minutes after
docetaxel, patients received premedication with a corticosteroid
and an antihistamine (the recommended regimen was hydrocor-
tisone 250 mg i.v. and diphenhydramine 50 mg i.v.). Patients
who completed 6 cycles of combination therapy without disease
progression or unacceptable toxicity continued to receive either
placebo or bavituximab 1 mg/kg or 3 mg/kg weekly until disease
progression or toxicity. There was no dose modiﬁcation of blinded
treatment.
Assessments
Safety assessments were performed on study day 1 of each cycle
and included history and physical examination, vital signs, ECOG
performance status, AE assessment, complete blood count, chem-
istries, coagulation parameters, D-dimer, human antichimeric
antibody (HACA), and electrocardiogram. D-dimer and coagulation
parameters were followed because of a hypothetical risk of bavi-
tuximab inducing a clinical antiphospholipid antibody syndrome.
AEs and their severity were classiﬁed using the Common Termi-
nology Criteria for Adverse Events version 4.02 (CTCAE).
Tumor response was assessed radiographically every 2 cycles
during combination treatment and every 3 cycles during the
monotherapy period. A subset of the overall study population
participated in a PK substudy. All patients, including those who
discontinued protocol therapy, were followed for response until
disease progression and for OS.
Statistical Analysis
Forty patients were planned for randomization to each study
treatment (120 patients total), assuming a 7.5% dropout rate, for 37
evaluable patients per arm. With a 1-sided a of 0.10, this provided
78% power to detect a difference between 8% ORR (control arm)
and 26%ORR (bavituximab arms). Separate analyses comparing the
docetaxel with placebo group with each of the docetaxel with bavi-
tuximab groups (1 mg/kg and 3 mg/kg) were planned. However,
because of labeling discrepancies of the blinded investigational
product, some patients in the placebo group received some doses of
bavituximab 1 mg/kg, and some patients in the bavituximab 1 mg/kg
group received some doses of placebo.As a result of these events, exploratory data analyses were per-
formed by comparing the bavituximab 3 mg/kg group with a
combined control group, including the bavituximab 1 mg/kg and
placebo groups. All results were reported for the intent-to-treat
population. Because this approach was not prespeciﬁed in the
protocol or the statistical analysis plan, the analyses presented are
considered exploratory.
Cox proportional hazard model parameter estimates were used to
analyze PFS and OS. This model included the following disease and
clinical characteristics: treatment, tumor stage (IIIB vs. IV), tumor
histology (adenocarcinoma vs. other), and number of organs
involved (1 vs.  2).
Results
A total of 121 patients were enrolled and randomized. The ﬁrst
patient enrolled in October of 2010 and the last patient enrolled in
October of 2011. Of the 121 patients enrolled, 119 received study
treatment. After study unblinding, discrepancies between some
patient PK sample test results and patient treatment code assign-
ments were discovered. An extensive review of these discrepancies
was completed, conﬁrming the initial observations and revealing
additional label discrepancies between vials labeled as placebo and
vials labeled as 1 mg/kg bavituximab. There was no evidence that
patients randomized to 3 mg/kg bavituximab received anything
other than accurately labeled investigational product. This was
concluded after retrieving used and unused vials of the investiga-
tional product, as well as all available patient samples for antidrug
antibody (ADA) testing. In the bavituximab 3 mg/kg arm, all tested
vials and samples were consistent with their labeling.
Because of the intact integrity of the data obtained from the 3
mg/kg bavituximab arm, additional exploratory efﬁcacy analyses
were performed. In the analyses, which are presented in this report,
the 3 mg/kg bavituximab group was compared with the combined
control group of 1 mg/kg bavituximab and placebo.
Patient Characteristics and Treatment Exposure
Of the 121 enrolled patients, 80 were in the combined control
group, and 41 were in the bavituximab 3 mg/kg group. De-
mographic and disease characteristics were generally well balanced
between the groups (Table 1).
Overall, 41 patients completed 6 cycles of combination treat-
ment. Of these, 29 received maintenance therapy with the blinded
investigational product. The median number of cycles administered
to patients was 4 for both groups. The mean total number of
blinded treatment doses administered was 13.7 in the combined
control placebo/bavituximab 1 mg/kg group and 16.8 in the bavi-
tuximab 3 mg/kg group. The median number of maintenance
treatment doses was 4 (range, 1-6) in the bavituximab 3 mg/kg
group and 4 (range, 1-6) in the combined control group. In the
safety population, 7 of 79 patients (8.9%) in the combined control
group had a dose reduction, whereas 3 of 40 patients (7.5%) in the
bavituximab 3 mg/kg group had a dose reduction. A patient was
considered to have had a dose reduction if the patient received a
planned docetaxel dose of  65 mg/m2.
Poststudy therapy was administered to 41.5% (17 of 41) of pa-
tients in the bavituximab 3 mg/kg group and to 31.3% (25 of 80) of
patients in the combined control group.Clinical Lung Cancer May 2016 - 171
Table 1 Patient Demographic and Disease Characteristics
Characteristic
Combined Control
(Placebo and
Bavituximab 1 mg/kg)
(n [ 80)
Bavituximab
3 mg/kg
(n [ 41)
Mean Age ± SD, Years 60  11 61  9
Sex, n (%)
Male 49 (61) 27 (66)
Female 31 (39) 14 (34)
Race, n (%)
White 54 (68) 20 (49)
South Asian 24 (30) 18 (44)
Black 2 (2) 3 (7)
Stage, n (%)
IIIB 7 (9) 4 (10)
IV 73 (91) 37 (90)
Histology, n (%)
Adenocarcinoma 72 (90) 32 (78)
Other 8 (10) 9 (22)
ECOG Performance
Status, n (%)
n [ 79 n [ 40
0-1 69 (87) 31 (77)
2 10 (13) 9 (23)
Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.
Docetaxel and Bavituximab in Nonsquamous NSCLC
172 -Efﬁcacy
Because of the labeling error and pooling of the placebo and
bavituximab 1 mg/kg arms, efﬁcacy analyses are considered
exploratory. The primary end point of ORR was 11.3% (95%
conﬁdence interval [CI], 4.3%-8.2%) in the combined control
placebo/bavituximab 1 mg/kg group and 17.1% (95% CI, 5.6%-
28.6%) in the bavituximab 3 mg/kg group (P ¼ .37). Stable disease
was observed in 50.0% and 48.8% of patients in the groups,
respectively. Radiographic response is summarized in Table 2.
Median PFS, on the basis of the investigator’s assessment, was 4.5
months in the bavituximab 3 mg/kg arm, compared with 3.3
months in the combined control group (hazard ratio [HR], 0.74;Table 2 Best Radiographic Response According to Treatment
Group
Response
Combined Control
(Placebo and
Bavituximab
1 mg/kg) (n [ 80)
Bavituximab
3 mg/kg (n [ 41)
CR 1 (1.3) 0 (0.0)
PR 8 (10.0) 7 (17.1)
SD 40 (50.0) 20 (48.8)
PD 14 (17.5) 6 (14.6)
Missing or Not
Evaluable
10 (12.5) 4 (9.8)
Non-CR/Non-PD 7 (8.8) 4 (9.8)
Data are presented as n (%). Intent-to-treat population. Column percentage totals might not
equal 100 due to rounding.
Clinical Lung Cancer May 201695% CI, 0.45-1.21; P ¼ .24; Figure 1). No statistically signiﬁcant
differences were observed when treatment groups were analyzed on
the basis of disease stage, histology, or number of organs involved
(P ¼ .73; HR, 0.913).
There was a trend toward improved OS in the bavituximab 3 mg/
kg group (Figure 2). In the bavituximab 3 mg/kg arm, median OS
was 11.7 months compared with 7.3 months in the combined
control group (HR, 0.66; 95% CI, 0.40-1.10; P ¼ .11). No sta-
tistically signiﬁcant differences were observed when treatment
groups were analyzed on the basis of clinical disease and previous
treatment characteristics in the Cox proportional hazard model.
Toxicity
In the combined control placebo/bavituximab 1 mg/kg group,
82% of patients experienced at least 1 AE during the study,
compared with 95% in the bavituximab 3 mg/kg group. The most
commonly reported AEs were fatigue, nausea, and neutropenia.
Grade  3 toxicity occurred in 35 patients (45%) in the combined
control group and in 22 patients (55%) in the bavituximab 3 mg/kg
group (Table 3). Discontinuation of study drug because of an AE
occurred in 9 patients (11%) in the combined control group and 9
patients (23%) in the bavituximab 3 mg/kg group.
Treatment-related AEs were reported in 34 patients (43%) in
the placebo/bavituximab 1 mg/kg group and in 25 patients (63%)
in the bavituximab 3 mg/kg group. The most frequently reported
treatment-related AEs in the combined control group were fatigue
(11%), asthenia (10%), and neutropenia (10%). The most
frequently reported treatment-related AEs in the bavituximab 3
mg/kg group were nausea (20%), fatigue (15%), and anorexia
(15%). No patient experienced a fatal event considered related to
the study treatment during the study. Grade 3 treatment-related
AEs occurred in 22 patients (55.0%) in the bavituximab 3 mg/
kg group and in 35 patients (44.3%) in the combined control
group. In the bavituximab 3 mg/kg arm, Grade  3 treatment-
related AEs occurring in at least 5% of patients included neu-
tropenia (22.5%), anemia (12.5%), leukopenia (7.5%), fatigue
(7.5%), asthenia (7.5%), palmar-plantar erythrodysesthesia syn-
drome (7.5%), febrile neutropenia (5.0%), and pneumonia
(5.0%). In the combined control group, Grade  3 treatment-
related AEs occurring in at least 5% of patients included neu-
tropenia (20.3%), leukopenia (11.4%), fatigue (10.1%), febrile
neutropenia (6.3%), and pneumonia (5.1%).
Overall, 7 serious thromboembolic AEs occurred in 6 patients
during the study: 5 patients in the placebo/bavituximab 1 mg/kg
group had events of pulmonary embolism (PE), cerebrovascular
accident (CVA), and deep vein thrombosis (DVT); 1 patient in the
3 mg/kg group had a DVT. All but 1 event was CTCAE Grade  3,
and all but 1 event resolved by the end of the study.
Pharmacokinetic Analysis
Seventeen patients from the overall study population (11 patients
in the placebo/bavituximab 1 mg/kg group and 6 patients in the
bavituximab 3 mg/kg group) participated in a PK substudy to
investigate the drugedrug interaction between bavituximab and
docetaxel. No signiﬁcant differences were observed in PK parame-
ters when bavituximab was administered with (cycle 2, day 1) or
without (cycle 1, day 8) docetaxel.
Figure 1 KaplaneMeier Curve for Progression-Free Survival (Intent-to-Treat Population)
Abbreviation: Bavi ¼ bavituximab.
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The presence of non-neutralizing (binding) HACAs, or ADAs,
was assessed at baseline and after administration of blinded study
drug using an electrochemiluminescence assay. A positive ADA
response was observed in 51% of the patients in the placebo/bavi-
tuximab 1 mg/kg group, conﬁrming that a signiﬁcant proportion of
patients in the combined control group were exposed to 1 mg/kg
bavituximab. Among patients in the bavituximab 3 mg/kg group,
65% had a conﬁrmed ADA-positive response. The presence of
binding ADAs did not correlate with the safety or efﬁcacy outcome
measures outlined in the study.
Discussion
Bavituximab is a unique, ﬁrst-in-class mAb targeting exposed PS.
Multiple preclinical models have shown the tumor-speciﬁc target-
ing,11,16,17 immune-modulating properties,8,22 vascular-targeting
effects,9,23 and antitumor efﬁcacy8,9,12,14,15,22,23 of bavituximab.
Further, the coadministration of cytotoxic chemotherapy enhances
PS exposure, resulting in complementary effects.14,15 On the basis
of the preclinical rationale and evidence, in this phase II clinical trial
the combination of bavituximab with docetaxel chemotherapy in
previously treated, advanced nonsquamous NSCLC patients was
evaluated. Although the patients were originally intended to be
randomized (1:1:1) to docetaxel with placebo, docetaxel with
bavituximab 1 mg/kg, and docetaxel with bavituximab 3 mg/kg,
labeling discrepancies of the blinded investigational productoccurred. As a result, some patients in the placebo group received
some doses of bavituximab 1 mg/kg, and some patients in the
bavituximab 1 mg/kg group received some doses of placebo.
However, patients in the bavituximab 3 mg/kg group were not
affected by this occurrence.
Because of these events, it is not possible to draw ﬁrm conclu-
sions from this trial. Nevertheless, some efﬁcacy and safety trends
merit discussion, particularly those observed in the docetaxel with
bavituximab 3 mg/kg arm. Notably, preclinical modeling suggests
that bavituximab 3 mg/kg weekly represents the best biologic dose
on the basis of target saturation at higher levels.18 In this trial, all
efﬁcacy end points (ORR, PFS, and OS) were numerically
improved in the docetaxel with bavituximab 3 mg/kg arm. Further,
clinical outcomes in this arm compare favorably with historic con-
trols. OS exceeded 11 months versus 7 to 9 months with docetaxel
monotherapy reported in earlier clinical trials.24-26 The ORR of
17%—although falling short of the 26% required to achieve the
primary end point of the trial—represents an approximate doubling
of rates typically seen with docetaxel. The clinical efﬁcacy of
docetaxel with bavituximab 3 mg/kg also appears comparable with
that of other docetaxel combinations, including the vascular endo-
thelial growth factor receptor antibody ramucirumab and the mul-
titargeted angiokinase inhibitor nintedanib.26,27
The coadministration of docetaxel and bavituximab appeared
feasible. PK analysis showed no clinically relevant drugedrug
interaction between the 2 drugs. Although > 50% of patients inClinical Lung Cancer May 2016 - 173
Figure 2 KaplaneMeier Curve for Overall Survival (Intent-to-Treat Population)
Abbreviation: Bavi ¼ bavituximab.
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actions were uncommon and mild. Toxicities that have been re-
ported with vascular-targeting therapies include bleeding,
thrombosis, hypertension, wound-healing complications, pro-
teinuria, and visceral perforations.28,29 In this trial, there was a
lower incidence of vascular events in the docetaxel with bavitux-
imab 3 mg/kg arm (n ¼ 1; DVT) than in the combined docetaxel
with placebo/bavituximab 1 mg/kg arm (n ¼ 5; DVT, PE, CVA).
There were no instances of clinically signiﬁcant, treatment-
emergent bleeding, proteinuria, hypertension, or visceral perfora-
tion. Further, vascular events in both arms of this trial did not
exceed those expected with docetaxel monotherapy or in the
general context of progressive advanced malignancy.30-33 Sepa-
rately, immune checkpoint inhibitors targeting CTLA4, PD1, and
PDL1 have been associated with numerous immune-related AEs,
including pneumonitis, colitis, hepatitis, hypophysitis, dermatitis,
and nephritis.1,34-37 In contrast, overt immune-related toxicities
have not been observed with bavituximab.
Because of the rapidly changing landscape of advanced NSCLC
treatment, the potential role of bavituximab warrants comment.
Immune checkpoint inhibitors, such as nivolumab and pem-
brolizumab, have shown unprecedented effects in broad pop-
ulations, offering patients more options than ever before. However,
despite the promise of these agents, the clear majority of patients
with NSCLC treated with checkpoint inhibitor immunotherapyClinical Lung Cancer May 2016either do not respond or eventually develop disease progression. At
that point, these patients remain in need of new and more effective
therapies. In contrast to approved checkpoint inhibitors, there is a
strong rationale and preclinical evidence supporting particular
beneﬁt when bavituximab is combined with cytotoxic chemo-
therapy.14,15 Finally, because of a distinct mechanism of action and
lack of apparent immune-mediated toxicity, the combination of
bavituximab with checkpoint inhibitors also represents a promising
strategy.
Conclusion
Bavituximab is a ﬁrst-in-class mAb targeting PS with immune
modulating and vascular-targeting properties. Although an investi-
gational product-labeling error in some study arms prevents drawing
ﬁrm conclusions from this phase II trial in previously treated,
advanced nonsquamous NSCLC, encouraging safety and efﬁcacy
signals were observed with the docetaxel with bavituximab 3 mg/kg
weekly arm. This combination is currently being studied in the
randomized phase 3 SUNRISE trial (NCT01999673). Although
the emergence of checkpoint inhibitor immunotherapy and doce-
taxel combinations have complicated the advanced NSCLC treat-
ment landscape, the potential for a novel and apparently
well-tolerated immunomodulatory agent to improve upon the efﬁ-
cacy of existing therapeutic options represents an important
consideration for these patients.
Table 3 Adverse Events Occurring in at Least 10% of Patients
in a Treatment Group (Safety Population)
Preferred Term
Placebo and
Bavituximab
1 mg/kg (n [ 79)
Bavituximab
3 mg/kg (n [ 40)
All Grades
Grades
3/4 All Grades
Grades
3/4
Fatigue 23 (29.1) 8 (10.1) 14 (35.0) 3 (7.5)
Nausea 22 (27.8) 0 (0.0) 15 (37.5) 0 (0.0)
Neutropenia 19 (24.1) 16 (20.3) 13 (32.5) 9 (22.5)
Cough 17 (21.5) 0 (0.0) 10 (25.0) 0 (0.0)
Edema, Peripheral 16 (20.3) 0 (0.0) 6 (15.0) 0 (0.0)
Diarrhea 16 (20.3) 0 (0.0) 7 (17.5) 1 (2.5)
Anemia 14 (17.7) 1 (1.3) 10 (25.0) 5 (12.5)
Alopecia 14 (17.7) 0 (0.0) 8 (20.0) 0 (0.0)
Pyrexia 13 (16.5) 0 (0.0) 8 (20.0) 0 (0.0)
Asthenia 13 (16.5) 1 (1.3) 12 (30.0) 3 (7.5)
Leukopenia 12 (15.2) 9 (11.4) 4 (10.0) 3 (7.5)
Anorexia 12 (15.2) 1 (1.3) 11 (27.5) 0 (0.0)
Constipation 12 (15.2) 0 (0.0) 7 (17.5) 1 (2.5)
Dyspnea 11 (13.9) 2 (2.5) 5 (12.5) 1 (2.5)
Vomiting 9 (11.4) 0 (0.0) 6 (15.0) 0 (0.0)
Arthralgia 8 (10.1) 0 (0.0) 8 (20.0) 1 (2.5)
Pain in Extremity 8 (10.1) 0 (0.0) 5 (12.5) 0 (0.0)
Chest Pain 8 (10.1) 1 (1.3) 8 (20.0) 0 (0.0)
Headache 8 (10.1) 1 (1.3) 3 (7.5) 1 (2.5)
Back Pain 8 (10.1) 0 (0.0) 8 (20.0) 0 (0.0)
Peripheral Sensory
Neuropathy
7 (8.9) 1 (1.3) 4 (10.0) 0 (0.0)
Productive Cough 7 (8.9) 0 (0.0) 7 (17.5) 0 (0.0)
Dizziness 6 (7.6) 1 (1.3) 4 (10.0) 0 (0.0)
Dyspnea, Exertional 5 (6.3) 0 (0.0) 4 (10.0) 0 (0.0)
Weight Decreased 5 (6.3) 0 (0.0) 4 (10.0) 0 (0.0)
Hypotension 4 (5.1) 1 (1.3) 6 (15.0) 0 (0.0)
Dehydration 4 (5.1) 1 (1.3) 4 (10.0) 1 (2.5)
Stomatitis 4 (5.1) 0 (0.0) 4 (10.0) 1 (2.5)
Abdominal Pain 3 (3.8) 0 (0.0) 5 (12.5) 0 (0.0)
Mucosal Inﬂammation 2 (2.5) 0 (0.0) 5 (12.5) 0 (0.0)
Data are presented as n (%).
David E. Gerber et alClinical Practice Points
 Bavituximab is a unique, ﬁrst-in-class, PS-targeting mAb with
immune-modulating and vascular-targeting properties.
 In preclinical models, administration of cytotoxic chemotherapy
results in increased exposure of PS and complementary effects
with PS-targeting therapies.
 This 3-arm, phase II clinical trial evaluated the combination of
bavituximab 1mg/kg i.v. weekly, bavituximab 3mg/kg i.v. weekly,
or placebo i.v. weekly with standard docetaxel 75 mg/m2 every 21
days. After study unblinding, vial coding discrepancies were
discovered in the placebo and bavituximab 1 mg/kg groups. Thus,
in exploratory analyses, data from these 2 groups were pooled to
form the control group and compared with the bavituximab 3mg/
kg group, which was not affected by the coding error.
 The combination of bavituximab with docetaxel did not appear
to substantially alter the safety proﬁle expected for docetaxel. The combination of docetaxel with bavituximab showed prom-
ising preliminary efﬁcacy in terms of ORR, PFS, and OS. A
phase III trial of docetaxel with or without bavituximab 3 mg/kg
(SUNRISE) is under way.Acknowledgments
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